CA-AVIZ-NETWORKS
30.11.2023 16:33:32 CET | Business Wire | Press release
Aviz Networks, a leader in open networking software for cloud-scale infrastructures serving telecom and enterprises, today announced it has added Cisco Investments to its latest funding expansion, joining existing investors, Moment Ventures, Accton and Wistron. This funding round, now reaching $10M, will accelerate customer momentum for Aviz’s multi-vendor, GenAI-based networking stack along with adoption of SONiC based open networking.
Aviz helps organizations achieve the performance and cost benefits of hyperscale networks by removing complexity and supplying AI-driven management features as part of a breakthrough Networking 3.0 software stack. Aviz’s stack supports the fast-growing SONiC open-source network OS (NOS) as well as multi-NOS environments and leverages the power of large-language-models (LLMs) to deliver unparalleled choice and capabilities. The company has seen rapid growth over the past 12 months, scaling its number of customers, revenue, and operational headcount to meet growing demand across multiple geographies. Aviz has witnessed a 250% growth in revenues with over 30 global customer engagements of various size.
Over the past three years, SONiC has emerged as a multibillion entity in the cloud and data center networking space, expected to reach $8B by 2027, according to research from communications industry analyst firm 650 Group.
“We are delighted to close this latest funding round that includes Accton, Cisco Investments, Moment Ventures, and Wistron. Our vision of delivering open, cloud & AI enabled networks for all enterprises and telecoms has rapidly taken shape as we partner with customers and our vendor ecosystem,” said Vishal Shukla, Co-Founder and CEO for Aviz. “Aviz continues to focus on supporting and leveraging community SONiC, and adding compelling innovations that enhance quality, drive down costs and accelerate time to deployment of open, cloud networks.”
“Accton is proud to be participating in this investment round with other global network leaders as it underscores our commitment to innovation in open networking. Aviz Networks has been extremely successful this year in the multi-billion dollar open network market, where SONiC plays a significant role. Accton is always pleased to collaborate with those that share our collective vision of employing AI and other cutting-edge technologies to meet the networking needs of enterprises and telcos,” said Jun Shi, CEO and President of Accton Group.
“Cisco is committed to accelerating innovation in networking to deliver comprehensive solutions to our customers,” says Aleem Rizvon, Vice President of Cisco Investments. “By investing in innovative startups, like Aviz, we are demonstrating our commitment to our partners and customers who value the open-source community.”
“Wistron is excited to see the multiple innovations and execution coming from Aviz as an early-stage company extending its reach to address the challenges of enterprise data center and cloud networks,” said William Lin, President of Enterprise & Networking B.G., Wistron Corporation. “Wistron is participating in this investment round so that our companies can work closely together to deliver the right solutions and substantial cost savings to enterprises as driven with robust SONiC edge deployments.”
About Aviz
Aviz Networks is a leading provider of solutions for Open, Cloud, and AI first networks. Aviz delivers switch platform agnostic, easy-to-use applications and APIs for network observability, orchestration, and assurance. Aviz also provides disaggregated support for multi-vendor SONiC deployments in data centers & edge networks. Aviz is on a mission to make SONiC a ubiquitous, accessible, and intelligent NOS for every stakeholder.
Learn more about Aviz at aviznetworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130443996/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom